Program
Methotrexate
Also written as “methotrexate”, “Methotrexate (MTX)” and “MTX”.
Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Gout · Arthritis, Psoriatic · Arthritis, Juvenile, led by 24 companies.
Drug pageMethotrexate: every studyMany companies study it; this page follows only the 93 they lead. All 627 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 360 open or running | phase 4since Apr 18, 2007 | Oct 21, 2005 | none ahead |
| Bristol-Myers Squibbits history only | 91 open or running | phase 4since Sep 4, 2015 | Jul 19, 2005 | none ahead |
| Pfizerits history only | 80 open or running | phase 4since Sep 8, 2005 | Sep 8, 2005 | none ahead |
| AbbVieits history only | 60 open or running | phase 4since May 25, 2010 | Sep 13, 2005 | none ahead |
| Johnson & Johnsonits history only | 60 open or running | phase 3since Dec 11, 2005 | Dec 11, 2005 | none ahead |
| Aldeyra Therapeuticsits history only | 31 open or running | phase 3since Oct 21, 2019 | Oct 21, 2019 | Dec 2029phase 3 · NCT07402876 |
| AstraZenecaits history only | 30 open or running | phase 4since Aug 23, 2023 | Sep 16, 2005 | none ahead |
| medacits history only | 31 open or running | phase 3since Jan 11, 2024 | May 14, 2013 | Nov 2026phase 3 · NCT06239311 |
| Merckits history only | 30 open or running | phase 3since Aug 18, 2006 | Aug 18, 2006 | none ahead |
| Halozyme Therapeuticsits history only | 20 open or running | phase 2since Jun 4, 2012 | Jun 4, 2012 | none ahead |
| Amneal Pharmaceuticalsits history only | 10 open or running | phase 1since Sep 15, 2016 | Sep 15, 2016 | none ahead |
| Azidus Brasilits history only | 10 open or running | phase 2since Apr 15, 2020 | Apr 15, 2020 | none ahead |
| Biocadits history only | 10 open or running | phase 3since Apr 4, 2016 | Apr 4, 2016 | none ahead |
| Biogenits history only | 10 open or running | phase 4since May 27, 2005 | May 27, 2005 | none ahead |
| Celltrionits history only | 10 open or running | phase 1since May 22, 2013 | May 22, 2013 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 4since Dec 4, 2012 | Dec 4, 2012 | none ahead |
| forsight-vision4its history only | 10 open or running | phase 2since Apr 24, 2014 | Apr 24, 2014 | none ahead |
| gema-biotech-s-aits history only | 10 open or running | phase 3since Apr 21, 2016 | Apr 21, 2016 | none ahead |
| jeffrey-j-crowley-mdits history only | 10 open or running | phase 3since Jul 12, 2017 | Jul 12, 2017 | none ahead |
| mediquest-therapeuticsits history only | 10 open or running | phase 2since Apr 22, 2008 | Apr 22, 2008 | none ahead |
| nordic-pharma-sasits history only | 10 open or running | phase 3since Sep 16, 2015 | Sep 16, 2015 | none ahead |
| prof-kristian-reichits history only | 10 open or running | phase 3since Jul 26, 2016 | Jul 26, 2016 | none ahead |
| Sanofi | 10 open or running | phase 3since Nov 13, 2014 | Nov 13, 2014 | none ahead |
| xbiotech-incits history only | 11 open or running | phase 2since Aug 22, 2024 | Aug 22, 2024 | Jan 15, 2027phase 2 · NCT06590090 |
Also a collaborator on its studies: Lakefront Biotherapeutics NV, Roche Pharma, Regeneron Pharmaceuticals, Integrated Therapeutics Group, Accutest Research Laboratories (I) Pvt., PPD DEVELOPMENT, LP, UCB, Immunex, Basilea Pharmaceutica International, Tanabe Pharma, Astellas Pharma US and Eisai.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Sanofi only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2014First study: phase 3 study in Arthritis, RheumatoidFirst studyNCT02293902 · 243 enrolled · Japan
TargetBeta
“Dihydrofolate reductase inhibitor; Dihydrofolate reductase inhibitor”ChEMBL 37, by rule
Other programs on DHFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Pemetrexedrule | Eli Lilly | phase 4 | 141 |
| pralatrexaterule | Aurobindo Pharma | phase 4 | 19 |
Studies
The one study Sanofi leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02293902Arthritis, Rheumatoid · Japan | 3 | Completed | Oct 2016 | 243 |
How it is read
Names in the registry
- “Methotrexate”, 71 entries
- “methotrexate”, 28 entries
- “Methotrexate (MTX)”, 7 entries
- “MTX”, 4 entries
- “methotrexate (MTX)”, 3 entries
Codes read as this program: ADX2191.
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 84 studies
- Psoriasis, 10 studies
- Gout, 8 studies
- Arthritis, Psoriatic, 4 studies
- Arthritis, Juvenile, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.